Browse categories and answer follow-up questions to refine your symptom profile.
Approach to the Critical Patient
Immediate priorities
First-hour stabilization
High-acuity triage for suspected acute chest syndrome in sickle cell disease
Respiratory distress
Hypoxemia relative to baseline
Continuous pulse oximetry
Target SpO2 92% or higher
Higher target for pregnancy or chronic hypoxemia baseline individualized
Supplemental oxygen
Nasal cannula escalation to face mask as needed
High-flow nasal cannula for persistent hypoxemia
Early blood bank notification
Type and screen
Extended red cell phenotype matching plan
Early hematology consultation
Transfusion strategy planning
Alloimmunization history review
Early ICU team notification triggers
Rapidly rising oxygen requirement
Altered mental status
Hemodynamic instability
Respiratory failure escalation
Noninvasive ventilation for increased work of breathing without contraindications
Close monitoring for fatigue and worsening hypoxemia
Intubation preparation
Difficult airway risk assessment
Post-intubation ventilator strategy for ARDS physiology
Post-intubation hypotension risk mitigation
Conservative induction dosing
Vasopressor readiness
Hemodynamic and monitoring goals
Monitoring bundle
Frequent vital signs
Respiratory rate trending
Temperature trending
Cardiac monitoring for hypoxemia and anemia stress
QT-prolonging medication review
Strict intake and output
Avoid fluid overload
Fluids strategy
Euvolemia goal
Isotonic maintenance only if poor oral intake
Avoid aggressive boluses without shock physiology
Shock pathway if present
Sepsis protocol integration
Point-of-care ultrasound for volume status
Key concepts
Working definition
New pulmonary infiltrate on imaging
With fever or respiratory symptoms
With chest pain or hypoxemia
Acute decline can occur within hours
Close reassessment cadence
Early multimodal therapy
Oxygenation support
Prevent hypoxemia driven sickling
Antibiotics for atypical and typical pathogens
Early administration in febrile or infiltrate cases
Lung expansion therapy
Incentive spirometry to reduce atelectasis
Transfusion for oxygen delivery and HbS reduction
Simple transfusion for moderate disease
Exchange transfusion for severe or progressive disease
History
Symptom profile and timeline
Presenting features
Chest pain
Pleuritic component
Rib infarction suspicion
Cough
Productive versus dry
Dyspnea
Exertional limitation change
Fever or chills
Peak temperature and duration
Wheeze
Asthma exacerbation overlap
Hemoptysis
Pulmonary embolism consideration
Timing
Symptom onset time
Rapid progression within 24 hours risk
Recent vaso-occlusive pain episode
Opioid use and hypoventilation risk
Sickle cell disease context
Genotype and baseline
HbSS
HbSC
HbS beta thalassemia
Baseline hemoglobin g/L
Baseline oxygen saturation
Prior acute chest syndrome episodes
Prior ICU admission
Prior exchange transfusion
Known triggers pattern
Disease-modifying therapy
Hydroxyurea use and adherence
Recent transfusion program
Voxelotor use
Crizanlizumab use
Risk factors and exposures
Infection exposures
Household viral illness
Recent influenza like illness
Thromboembolism risk
Prior VTE
Recent immobilization
Central venous catheter
Pulmonary comorbidity
Asthma diagnosis
Obstructive sleep apnea
Smoking or vaping exposure
Recent procedures
Surgery or anesthesia in last 2 weeks
Recent bronchoscopy
Transfusion safety history
Alloimmunization history
Known antibodies list
Prior delayed hemolytic transfusion reaction
Prior transfusion complications
Hyperhemolysis history
Transfusion associated circulatory overload history
Physical Exam
General and respiratory assessment
Severity markers
Work of breathing
Accessory muscle use
Inability to speak full sentences
Mental status
Somnolence from hypoxemia or opioids
Perfusion
Delayed capillary refill
Respiratory exam
Breath sounds
Focal crackles
Decreased air entry
Wheeze
Bronchospasm overlap
Pleural rub
Pleuritis consideration
Vital signs and oxygenation
Oxygenation and ventilation
SpO2 on room air and with oxygen
Comparison to known baseline
Respiratory rate trend
Tachypnea progression
Fever assessment
Temperature peak
Sepsis physiology evaluation
Hemodynamics
Hypotension
Sepsis or massive PE consideration
Tachycardia
Pain versus hypoxemia versus anemia
Cardiovascular and volume status
Cardiac exam
New murmur
High output state
Signs of right heart strain
Elevated JVP
Volume status exam
Peripheral edema
Fluid overload risk
Lung exam for overload pattern
Diffuse crackles
PITFALLS
Missed acute chest syndrome
Normal initial chest radiograph
Repeat imaging if clinical worsening
Pain crisis with hypoventilation
Atelectasis evolving to infiltrate
Asthma misattribution
Infiltrate and hypoxemia still treated as acute chest syndrome
Differential Diagnosis
Life-threatening pulmonary and cardiac causes
High-risk alternatives
Pulmonary embolism ICD-10 I26.99
Pleuritic pain
Unexplained tachycardia
Severe community acquired pneumonia ICD-10 J18.9
Lobar consolidation
Sepsis physiology
Acute respiratory distress syndrome ICD-10 J80
Bilateral opacities
Refractory hypoxemia
Acute heart failure ICD-10 I50.9
Volume overload signs
Cardiomegaly
Myocardial ischemia ICD-10 I21.9
Ischemic ECG changes
Troponin elevation
Mimics and overlapping sickle complications
Sickle related considerations
Atelectasis ICD-10 J98.11
Hypoventilation
Postoperative state
Fat embolism syndrome
Neurologic changes
Petechiae
Rib infarction
Localized chest wall tenderness
Hypoventilation due to pain
Acute asthma exacerbation ICD-10 J45.901
Wheeze predominant
Prior asthma history
Coding aligned sickle chest entities
Sickle cell disease with acute chest syndrome
ICD-10 D57.01 HbSS disease with acute chest syndrome
ICD-10 D57.211 HbSC disease with acute chest syndrome
ICD-10 D57.411 Sickle beta plus thalassemia with acute chest syndrome
ICD-10 D57.811 Other sickle cell disorders with acute chest syndrome
Laboratory Tests
Core labs and trending
Baseline severity and trend panel
Complete blood count with differential
Hemoglobin g/L trend from baseline
Drop 10 g/L or more from baseline as higher risk marker
Platelets trend
Falling platelets as severe disease marker
Reticulocyte count
Bone marrow response adequacy
Inappropriately low reticulocytes suggests aplasia or marrow suppression
Electrolytes and creatinine mmol/L
Renal function for antibiotic dosing
Acute kidney injury impact on fluid strategy
Hemolysis and hepatic panel
Total bilirubin mmol/L
Hemolysis baseline context
AST
Hepatic injury screen
ALT
Hepatic injury screen
Infection evaluation
Microbiology bundle
Blood cultures
Before antibiotics when feasible without delay
Low sensitivity but important for bacteremia detection
Respiratory viral PCR panel
Influenza
Antiviral decision support
SARS-CoV-2
Isolation and treatment implications
Sputum culture
If productive cough and able to expectorate
Limited yield but may guide de-escalation
Inflammatory markers
C reactive protein
Trend support for infection or inflammation
Procalcitonin
Adjunct only
Do not use alone to withhold antibiotics
Gas exchange assessment
Oxygenation assessment tests
Arterial blood gas
PaO2 mmHg
PaO2 under 60 mmHg as severe marker
PaCO2 mmHg
Rising PaCO2 as fatigue marker
Venous blood gas
If ABG not feasible and clinical stability
PaO2 not interchangeable with ABG
Diagnostic Tests
Scoring Systems
Severity stratification framework
No universally validated acute chest syndrome score
Use physiologic severity features for escalation decisions
High severity feature set
Oxygen requirement rapidly increasing
Escalation to ICU evaluation
Multilobar infiltrates
Exchange transfusion consideration
PaO2 under 60 mmHg on room air
Severe classification
Need for noninvasive ventilation
Severe classification
Need for intubation
Severe classification
Hemodynamic instability
Sepsis or massive PE evaluation
Moderate severity feature set
New infiltrate with mild hypoxemia responsive to low-flow oxygen
Simple transfusion consideration
Fever with suspected pneumonia
Antibiotics and admission
MRI
MRI chest role
Limited acute utility
Longer acquisition time
Motion sensitivity in tachypnea
Indications
Alternative diagnosis evaluation when CT contraindicated
Mediastinal mass
Research or subacute complications
Pulmonary infarction characterization
Contraindications
Unstable respiratory status
Non-MRI compatible implants
CT
CT chest pathways
CT pulmonary angiography
Suspected pulmonary embolism
Pleuritic pain out of proportion
Unexplained tachycardia
D-dimer not reliable for exclusion in sickle cell disease
Contrast risk mitigation
Creatinine based risk assessment
CT chest without angiography
Complication evaluation
Effusion
Abscess
Alternative diagnosis
Interpretation pearls
Atelectasis can coexist with infiltrate
Treat as acute chest syndrome when clinical criteria met
Ultrasound
Point-of-care ultrasound applications
Lung ultrasound
Consolidation
Dynamic air bronchograms support pneumonia
Pleural effusion
Procedural planning support
B-lines
Pulmonary edema consideration in fluid overload
Cardiac ultrasound
Right ventricular strain
Pulmonary embolism consideration
LV function
Cardiogenic contribution evaluation
IVC ultrasound
Volume status adjunct
Avoid over-resuscitation with fluids
Disposition
Admission and level of care
Default disposition
Hospital admission for suspected acute chest syndrome
Early deterioration risk
Need for serial reassessment
ICU or step-down criteria
Escalating oxygen requirement
High-flow nasal cannula need
Noninvasive ventilation need
PaO2 under 60 mmHg
Severe classification
Multilobar infiltrates
High risk for respiratory failure
Altered mental status
Hypercapnia or hypoxemia concern
Hemodynamic instability
Sepsis pathway integration
Transfer criteria
No exchange transfusion capability onsite
Severe or rapidly progressive disease
Lack of ICU resources
Need for ventilatory support
Discharge rare scenarios
Discharge uncommon
Consider only after inpatient observation course
Stable on room air at baseline saturation
Improving symptoms
Reliable follow-up within 24 to 48 hours
Treatment
Core bundle
Initial therapy bundle
Oxygen support
Titrate to SpO2 92% or higher
Consider higher targets in pregnancy
Antibiotics
Ceftriaxone IV 1 g every 24 hours
Severe illness dose 2 g every 24 hours
Azithromycin IV or PO 500 mg day 1
Then 250 mg daily days 2 to 5
Penicillin allergy alternative
Levofloxacin IV or PO 750 mg daily
MRSA coverage when indicated
Vancomycin IV 15 to 20 mg per kg
Trough or AUC guided dosing per local protocol
Lung expansion therapy
Incentive spirometry 10 breaths every 2 hours while awake
Early use reduces atelectasis risk
Early ambulation as tolerated
VTE prevention and ventilation support
Analgesia and sedation safety
Opioid based pain control with monitoring
Avoid oversedation and hypoventilation
Multimodal adjuncts
Acetaminophen PO 650 to 1000 mg every 6 hours
Maximum 4000 mg per day
Ketorolac IV 15 mg every 6 hours
Maximum 60 mg per day
Avoid in renal dysfunction and bleeding risk
Bronchodilators and airway inflammation
Bronchospasm management
Albuterol inhaled 4 to 8 puffs every 20 minutes for 1 hour
Then 2 to 4 puffs every 4 hours as needed
Ipratropium inhaled 4 puffs every 20 minutes for 1 hour
Then every 6 hours as needed
Systemic corticosteroids
Routine use avoided
Rebound vaso-occlusive pain risk after discontinuation
Selective use
Severe asthma exacerbation overlap
Prednisone PO 40 to 60 mg daily
Short course with plan for taper and close follow-up
Transfusion strategy
Simple transfusion
Indications
Hemoglobin drop 10 g/L or more from baseline with symptoms
Hypoxemia not corrected with low-flow oxygen
Progressive infiltrate without severe criteria
Targets
Post-transfusion hemoglobin around 100 g/L
Avoid overtransfusion and hyperviscosity
Product selection
Leukoreduced packed red blood cells
Febrile reaction reduction
Extended phenotype matched units
Rh and Kell matched at minimum when feasible
Exchange transfusion
Indications
Rapid clinical deterioration
Escalating oxygen requirement over hours
Multilobar infiltrates
Severe classification
PaO2 under 60 mmHg on room air
Severe classification
Need for noninvasive ventilation
Severe classification
Need for intubation
Severe classification
Goals
Hemoglobin S fraction reduction target under 30%
Use local protocol and hematology guidance
Hemoglobin target around 100 g/L
Avoid hyperviscosity
Logistics
Automated erythrocytapheresis preferred when available
Faster HbS reduction
Transfusion complication mitigation
Alloimmunization risk reduction
Antibody history reconciliation before issuing blood
Delayed hemolytic transfusion reaction vigilance
New pain and falling hemoglobin after transfusion
Anticoagulation and VTE prevention
VTE prophylaxis for admitted patients without contraindication
Enoxaparin SC 40 mg daily
Renal dosing adjustment per local protocol
Unfractionated heparin SC 5000 units every 8 to 12 hours
Alternative when renal dysfunction
Therapeutic anticoagulation only with confirmed indication
Confirmed pulmonary embolism
DOAC selection or heparin based on clinical context
Adjuncts and escalation therapies
Antibiotic escalation triggers
Septic shock
Broad spectrum coverage per local sepsis guideline
Immunocompromised state
Expanded coverage and infectious disease consultation
Antiviral therapy
Influenza suspected or confirmed
Oseltamivir PO 75 mg twice daily for 5 days
Initiate regardless of symptom duration when hospitalized
Pleural effusion management
Large effusion with respiratory compromise
Diagnostic thoracentesis
Therapeutic drainage with ultrasound guidance
Ventilation strategy for ARDS physiology
Lung protective ventilation
Tidal volume 6 ml per kg predicted body weight
Plateau pressure 30 cm H2O or lower
Prone positioning for refractory hypoxemia
ICU protocol based implementation
Special Populations
Pregnancy
Pregnancy considerations
Maternal oxygenation priority
Higher SpO2 target individualized
Early ICU involvement for worsening hypoxemia
Obstetrics consultation early
Fetal monitoring plan
Medication safety
Avoid NSAIDs in later gestation when contraindicated
Antibiotics selection compatible with pregnancy
Transfusion thresholds lower for maternal fetal oxygen delivery
Hematology and obstetrics joint decision
Geriatric
Older adult considerations
Higher cardiopulmonary comorbidity burden
Lower tolerance for anemia and hypoxemia
Fluid overload susceptibility
Conservative IV fluid approach
Renal dosing adjustments
Antibiotics and anticoagulation
Pediatrics
Pediatric acute chest syndrome
Higher viral trigger prevalence
Viral PCR utility
Weight-based antibiotic dosing
Ceftriaxone IV 50 mg per kg every 24 hours
Maximum 2 g daily
Azithromycin IV or PO 10 mg per kg day 1
Maximum 500 mg
Then 5 mg per kg daily days 2 to 5
Maximum 250 mg
Transfusion dosing
Packed red blood cells 10 ml per kg
Target hemoglobin around 100 g/L
Incentive spirometry adaptation
Bubble blowing or age-appropriate lung expansion play
Background
Epidemiology
Epidemiologic overview
Common cause of hospitalization and mortality in sickle cell disease
Occurs in both children and adults
Peak occurrence patterns
Children higher frequency
Adults higher severity and ICU need
Recurrence risk
Prior acute chest syndrome increases future risk
Pathophysiology
Mechanisms
Pulmonary vaso-occlusion from sickling
Hypoxemia amplifies sickling cascade
Infection triggers
Viral and atypical bacterial pathogens common
Atelectasis and hypoventilation
Pain and opioid effect
Reduced lung expansion
Fat embolism from bone marrow necrosis
Sudden hypoxemia and neurologic features
Ventilation perfusion mismatch
Shunt physiology with infiltrates
Therapeutic Considerations
Rationale for key interventions
Oxygen therapy
Reduces hypoxemia driven sickling
Antibiotics
Infection common and difficult to exclude early
Incentive spirometry
Reduces atelectasis progression
Transfusion
Improves oxygen carrying capacity
Reduces HbS fraction when exchange performed
Avoidance of overhydration
Pulmonary edema risk in compromised lungs
Patient Discharge Instructions
copy discharge instructions
Discharge after acute chest syndrome hospitalization
Medications
Complete prescribed antibiotic course
Continue home sickle therapies as directed
Breathing exercises
Incentive spirometry use several times daily for 3 to 5 days
Hydration and activity
Regular oral fluids
Gentle ambulation daily
Return immediately for
Worsening shortness of breath
Chest pain worsening
Fever 38.0 C or higher
New wheeze not relieved by inhaler
Fainting or severe weakness
Blue lips or fingers
Follow-up
Hematology visit within 1 week
Primary care visit within 1 to 2 weeks
Repeat chest imaging only if symptoms persist or recur
References
Clinical guidelines and key sources
Guideline sources
American Society of Hematology guidelines on sickle cell disease acute complications
Acute chest syndrome management recommendations
NHLBI evidence-based management of sickle cell disease expert panel report
Acute chest syndrome and pain management sections
British Society for Haematology sickle cell disease guidelines
Transfusion and acute chest syndrome guidance
Infectious Diseases Society of America community acquired pneumonia guidance
Empiric antibiotic framework for hospitalized pneumonia
Evidence summaries and consensus
Evidence notes
Simple transfusion improves oxygen delivery and may halt progression in moderate disease
Hyperviscosity risk when hemoglobin rises excessively
Exchange transfusion reduces HbS fraction rapidly in severe disease
Preferred when respiratory failure imminent
Systemic corticosteroids associated with rebound pain episodes in some studies
Avoid routine use without asthma indication
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.